EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|June 1, 2006
C1 inhibitors opening doors
C1-INH treatment shortened the mean duration of abdominal attacksfrom 92 to 40 hours and the mean maximal pain score declined from8.6 to 4.5.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Tilrekimig Phase 2 Data Show EASI 75 Gains in Atopic Dermatitis
4
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
5